Source comparison
Does PT-141 Help Hypoactive Sexual Desire Research? Comparison
Mechanism of Action MC4R agonist in hypothalamus Serotonin/dopamine modulation Androgen receptor activation PT-141 is the only non-hormonal, on-demand option with validated CNS mechanism Dosing Schedule On-demand subcutaneous injection 45 min before activity D
This comparison does not assign a generated winner or score.
- Mechanism of Action
- MC4R agonist in hypothalamus
- Serotonin/dopamine modulation
- Androgen receptor activation
- PT-141 is the only non-hormonal, on-demand option with validated CNS mechanism
- Dosing Schedule
- On-demand subcutaneous injection 45 min before activity
- Daily oral tablet regardless of activity
- Daily transdermal gel or biweekly injection
- PT-141's on-demand profile reduces systemic exposure and side-effect burden
- Primary Side Effects
- Nausea (40%), flushing (20%), transient BP increase
- Sedation, dizziness, alcohol interaction (black-box warning)
- Virilisation, lipid changes, cardiovascular risk in some populations
- PT-141 avoids the CNS depression and drug interactions seen with flibanserin
- Clinical Response Rate
- 25% achieve meaningful improvement vs 17% placebo
- 9–14% achieve meaningful improvement vs placebo
- Highly variable; 30–50% respond if baseline testosterone <25 ng/dL
- PT-141 shows superior response in women with normal baseline hormone levels
- FDA Approval Status
- Approved 2019 for premenopausal HSDD
- Approved 2015 for premenopausal HSDD
- Off-label for female HSDD; approved only for male hypogonadism
- PT-141 and flibanserin are the only FDA-approved agents specifically for female HSDD